Omeros Corporation reported a net loss of $31.4 million, or $0.54 per share, for the fourth quarter ended December 31, 2024. For the full year 2024, the net loss was $156.8 million, or $2.70 per share, compared to a net loss of $117.8 million, or $1.88 per share, in 2023.
As of December 31, 2024, cash and short-term investments totaled $90.1 million, representing a decrease of $81.7 million from December 31, 2023. Cash used in operations for the fourth quarter was $29.0 million, reflecting significant cost outlays including $21.7 million for convertible senior notes repurchase and $19.1 million for narsoplimab drug substance.
The company confirmed that its narsoplimab BLA for TA-TMA was resubmitted to the FDA earlier in March 2025, with the European MAA slated for submission in the coming quarter. OMIDRIA royalties for Q4 2024 were $10.1 million on Rayner’s U.S. net sales of $33.6 million, an increase from the prior quarter.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.